Chromocell Therapeutics Corp.
CHRO
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.9M
Close$
$-0.30
122.2% downside
Current Fair Value
122.2% downsideOvervalued by 122.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.90 Million |
|---|---|
| Enterprise Value | $3.84 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-23.04 |
| Beta | 3.29 |
| Outstanding Shares | 3,311,742 |
Return
| Return on Equity | -146.97% |
|---|---|
| Return on Assets | -35.49% |
| Return on Invested Capital | -27.75% |
Valuation & Multiples
| P/E Ratio | -0.09 |
|---|---|
| PEG | -0.02 |
| Price to Sales | 0.17 |
| Price to Book Ratio | 0.14 |
| Enterprise Value to Revenue | 0.14 |
| Enterprise Value to EBIT | -0.12 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 7.01 |
| Debt to Equity | 0.77 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
March 19, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data